Web of Science: 22 citations, Scopus: 24 citations, Google Scholar: citations,
Direct medical costs attributable to type 2 diabetes mellitus : a population-based study in Catalonia, Spain
Mata Cases, Manel (CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM))
Casajuana, Marc (Universitat Autònoma de Barcelona)
Franch Nadal, Josep (Institut Català de la Salut)
Casellas, Aina (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Castell, Conxa (Generalitat de Catalunya. Departament de Salut)
Vinagre Torres, Irene (Universitat de Barcelona)
Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bolíbar, Bonaventura (Universitat Autònoma de Barcelona)

Date: 2016
Abstract: We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, selfmonitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110. 1 and €1803. 6 for diabetic and non-diabetic subjects, respectively (difference €1306. 6; i. e. , 72. 4 % increased cost). The costs of hospitalizations were €1303. 1 and €801. 6 (62. 0 % increase), and medication costs were €925. 0 and €489. 2 (89. 1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41. 9 and 29. 7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin [7 %; [53 mmol/mol) had average costs of €3296. 5 versus €2848. 5 for patients with good control. In the absence of macrovascular complications, average costs were €3008. 1 for diabetic and €1612. 4 for non-diabetic subjects, while its presence increased costs to €4814. 6 and €3306. 8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications.
Note: Número d'acord de subvenció ISCIII/RD06/0018
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Type 2 diabetes ; Costs ; Primary care ; Retrospective ; Population database ; Catalonia ; Spain ; I1 ; H75
Published in: The European Journal of Health Economics, Vol. 17, Issue 8 (November 2016) , p. 1001-1010, ISSN 1618-7601

PMID: 26542160
DOI: 10.1007/s10198-015-0742-5


10 p, 440.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles

 Record created 2018-01-31, last modified 2019-02-23



   Favorit i Compartir